| Non-Small Cell Lung Carcinoma

Abraxane vs Braftovi

Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.

Deep comparison between: Abraxane vs Braftovi with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsBraftovi has a higher rate of injection site reactions vs Abraxane based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Braftovi but not Abraxane, including UnitedHealthcare

Category

Abraxane

Braftovi

At A Glance

RouteIV infusion

FrequencyWeekly to every 3 weeks

ClassMicrotubule inhibitor

RouteOral

FrequencyOnce daily

ClassBRAF inhibitor

Indications

Carcinoma breast stage IV
Non-Small Cell Lung Carcinoma
Adenocarcinoma of pancreas

melanoma
Colorectal Carcinoma
Non-Small Cell Lung Carcinoma

Dosing

Carcinoma breast stage IV 260 mg/m2 IV over 30 minutes every 3 weeks.

Non-Small Cell Lung Carcinoma 100 mg/m2 IV over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE.

Adenocarcinoma of pancreas 125 mg/m2 IV over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8, and 15 of each 28-day cycle immediately after ABRAXANE.

melanoma, Non-Small Cell Lung Carcinoma 450 mg (six 75 mg capsules) orally once daily in combination with binimetinib until disease progression or unacceptable toxicity.

Colorectal Carcinoma 300 mg (four 75 mg capsules) orally once daily until disease progression or unacceptable toxicity, in combination with biweekly cetuximab and mFOLFOX6 or FOLFIRI, or weekly cetuximab.

Contraindications

Baseline neutrophil count below 1500 cells/mm3
History of severe hypersensitivity reaction to ABRAXANE

—

Drug Interactions

1247View drug interactions

1207View drug interactions

Adverse Reactions

Most common (>=20%) Alopecia, neutropenia, sensory/peripheral neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, diarrhea, thrombocytopenia, peripheral edema, pyrexia, vomiting, decreased appetite, rash, dehydration

Serious Anemia, pneumonia, pyrexia, dehydration, vomiting

Postmarketing Severe hypersensitivity reactions, congestive heart failure, left ventricular dysfunction, atrioventricular block, pneumonitis, interstitial pneumonia, pulmonary embolism, cranial nerve palsies, vocal cord paresis, autonomic neuropathy, cystoid macular edema, hepatic necrosis, intestinal obstruction, intestinal perforation, pancreatitis, ischemic colitis, tumor lysis syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis

Most common (>=25%) Fatigue, nausea, vomiting, diarrhea, abdominal pain, arthralgia, peripheral neuropathy, decreased appetite, rash, constipation, musculoskeletal pain, hemorrhage, pyrexia.

Serious New primary malignancies, cardiomyopathy, hepatotoxicity, hemorrhage, uveitis, QT prolongation, embryo-fetal toxicity.

Pharmacology

ABRAXANE is a microtubule inhibitor that promotes assembly and stabilization of microtubules from tubulin dimers, inhibiting the normal dynamic reorganization of the microtubule network essential for vital interphase and mitotic cellular functions.

Encorafenib is a kinase inhibitor that targets BRAF V600E as well as wild-type BRAF and CRAF, blocking constitutively activated BRAF kinase signaling driven by BRAF V600 mutations that stimulates tumor cell growth; in combination with binimetinib, it targets two kinases in the RAS/RAF/MEK/ERK pathway for greater anti-tumor activity.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Abraxane